BackBiogen Overview

Biogen EBIT

Biogen's EBIT is $650M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$78.50M
↓ 85.91% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$653.30M
↑ 17.23% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Biogen (BIIB.SW) FAQ

The latest EBIT for BIIB.SW is $650M as of September 2026. That compares with $560M in the prior-year period — up 17.2% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Biogen's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIIB.SW's EBIT moved from $560M to $650M — a 17.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biogen's operating scale or balance-sheet position.

Against Healthcare companies, BIIB.SW currently prints $650M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Biogen's growth, margins, and balance sheet.

A EBIT figure of $650M for BIIB.SW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting BIIB.SW's EBIT ($650M), review year-over-year change from $560M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers